Srdan Verstovsek, MD, The University of Texas, MD Anderson Cancer Center, Houston, TX, discusses what the future may hold with regards to treatment strategies for myeloproliferative neoplasms (MPNs). For essential thrombocythemia and polycythemia vera, Dr Verstovsek talks on the use of ropeginterferon, and for myelofibrosis Dr Verstovsek outlines the benefits of JAK inhibitor use, novel drugs to target anemia and new combinations and approaches with JAK inhibitors. This interview took place at the Texas MPN Workshop: Second Annual Workshop and Meeting in 2021.

свернуть